- Home
- AUTL vs HRZN Comparison
AUTL vs HRZN Comparison
Compare AUTL & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- HRZN
- Stock Information
- Founded
- AUTL 2014
- HRZN 2008
- Country
- AUTL United Kingdom
- HRZN United States
- Employees
- AUTL N/A
- HRZN N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- HRZN Finance/Investors Services
- Sector
- AUTL Health Care
- HRZN Finance
- Exchange
- AUTL Nasdaq
- HRZN Nasdaq
- Market Cap
- AUTL 359.3M
- HRZN 352.9M
- IPO Year
- AUTL 2018
- HRZN 2010
- Fundamental
- Price
- AUTL $1.27
- HRZN $7.55
- Analyst Decision
- AUTL Strong Buy
- HRZN Hold
- Analyst Count
- AUTL 5
- HRZN 5
- Target Price
- AUTL $9.32
- HRZN $9.20
- AVG Volume (30 Days)
- AUTL 2.4M
- HRZN 603.8K
- Earning Date
- AUTL 05-08-2025
- HRZN 04-29-2025
- Dividend Yield
- AUTL N/A
- HRZN 17.48%
- EPS Growth
- AUTL N/A
- HRZN N/A
- EPS
- AUTL N/A
- HRZN N/A
- Revenue
- AUTL $9,011,000.00
- HRZN $98,302,000.00
- Revenue This Year
- AUTL $277.74
- HRZN $12.95
- Revenue Next Year
- AUTL $221.89
- HRZN $8.81
- P/E Ratio
- AUTL N/A
- HRZN N/A
- Revenue Growth
- AUTL N/A
- HRZN N/A
- 52 Week Low
- AUTL $1.11
- HRZN $7.12
- 52 Week High
- AUTL $5.00
- HRZN $12.63
- Technical
- Relative Strength Index (RSI)
- AUTL 43.50
- HRZN 38.80
- Support Level
- AUTL $1.15
- HRZN $7.28
- Resistance Level
- AUTL $1.44
- HRZN $7.71
- Average True Range (ATR)
- AUTL 0.13
- HRZN 0.26
- MACD
- AUTL 0.01
- HRZN -0.01
- Stochastic Oscillator
- AUTL 29.27
- HRZN 22.05
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.